UBS Raises price Target on Foundation Medicine (FMI) to $22

September 21, 2016 9:33 AM EDT
Get Alerts FMI Hot Sheet
Price: $23.35 +3.27%

Rating Summary:
    2 Buy, 7 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 9 | New: 77
Trade FMI Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

UBS reiterated a Neutral rating on Foundation Medicine (NASDAQ: FMI), and raised the price target to $22.00 (from $16.00), following the company's announced expanded Local Coverage Determination.

Analyst Jonathan Groberg commented, "Palmetto, a Medicare contractor, announced last Thursday an expanded Local Coverage Determination (LCD) to include all stage IIIB/IV non-small cell lung cancer (NSCLC) patients. This new policy now provides coverage for comprehensive genomic profiling (CGP) for metastatic NSCLC patients who have not been tested for genomic mutations or who have tested negative for EGFR mutations. This is important for patients as CGP detected alterations may indicate eligibility for targeted treatment or immunotherapy."

For an analyst ratings summary and ratings history on Foundation Medicine click here. For more ratings news on Foundation Medicine click here.

Shares of Foundation Medicine closed at $23.60 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

UBS

Add Your Comment